CM
CMPS.US Compass Pathways Plc
- Market cap
- USD 1.28B
- P/E
- -
- P/B
- 9.10x
- ROE
- -161.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CMPS.US undervalued?
Graham numberThe Graham number of Compass Pathways Plc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Compass Pathways Plc fundamental analysis
No fundamental analysis for Compass Pathways Plc yet.
Compass Pathways Plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Compass Pathways Plc
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in Augu…
Full company profileCompass Pathways Plc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Compass Pathways Plc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | -63.0K | -113K | -175K | -330K | -243K | -233K | -217K | - |
| Operating Income | -12.5M | -21.2M | -51.8M | -83.2M | -110M | -137M | -178M | -179M | -202M |
| EBITDA | -10.5M | -22.3M | -64.9M | -71.4M | -90.8M | -115M | -149M | -286M | -225M |
| Net Income | -13.2M | -19.6M | -60.8M | -71.7M | -91.5M | -118M | -155M | -288M | -230M |
| EPS | -2.35 | -0.90 | -1.69 | -1.79 | -2.16 | -2.32 | -2.30 | -3.08 | -1.41 |
| Balance Sheet | |||||||||
| Total Assets | 26.4M | 32.4M | 203M | 301M | 197M | 276M | 214M | 210M | 519M |
| Total Liabilities | 40.8M | 23.9M | 6.90M | 16.5M | 16.0M | 50.2M | 59.0M | 263M | 377M |
| Shareholders' Equity | -14.4M | 8.52M | 197M | 284M | 181M | 226M | 155M | -52.8M | 142M |
| Cash & Short-term Investments | 22.9M | 25.0M | 190M | 273M | 143M | 220M | 165M | 150M | 444M |
| Total Debt | - | 21.1M | - | 3.61M | 1.93M | 33.1M | 32.2M | 20.9M | 54.4M |
| Cash Flow | |||||||||
| Operating Cash Flow | -9.80M | -17.8M | -41.4M | -67.7M | -105M | -97.4M | -119M | -157M | -185M |
| Capital Expenditure | 130K | 165K | 131K | 334K | 596K | 66.0K | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -9.93M | -18.0M | -41.5M | -68.1M | -106M | -97.4M | -119M | -157M | -185M |
| Ratios | |||||||||
| ROE | - | -230.2% | -30.9% | -25.2% | -50.5% | -52.5% | -100.3% | - | -161.8% |
| ROA | -50.1% | -60.6% | -29.9% | -23.8% | -46.4% | -42.9% | -72.6% | -136.8% | -44.3% |
| Debt to Equity | - | 2.48x | - | 0.01x | 0.01x | 0.15x | 0.21x | - | 0.38x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Compass Pathways Plc dividends
Compass Pathways Plc has not paid dividends in the last 8 fiscal years.
Who owns Compass Pathways Plc
- Insiders 9.61%
- Institutions 69.34%
- Public & others 21.05%
- Shares outstanding 142M
- Free float 110M
Top funds holding CMPS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| ARK Genomic Revolution ETF | 5.11M | 3.60% | +0.58% | Oct 2026 |
| BIT Global Technology Leaders R-I | 2.61M | 1.84% | +49.68% | Jul 2026 |
| Candriam Eqs L Biotech C USD Cap | 1.02M | 0.72% | 0.00% | Apr 2026 |
| iShares Biotechnology ETF | 886K | 0.63% | -0.19% | Oct 2026 |
| TEQ - Disruptive Technologies - I-II | 529K | 0.37% | +16.93% | Sep 2026 |
| AdvisorShares Psychedelics ETF | 458K | 0.32% | 0.00% | Oct 2026 |
| Militia Long/Short Equity ETF | 429K | 0.30% | 0.00% | Oct 2026 |
| International Biotechnology Ord | 329K | 0.23% | 0.00% | Jul 2026 |
| ARK Genomic Revolution ETF A USD Acc | 328K | 0.23% | 0.00% | Oct 2026 |
| L&G Healthcare Tech & Innovt ETF USD Acc | 295K | 0.21% | 0.00% | Oct 2026 |
| T. Rowe Price Integrated US Sm Gr Eq | 269K | 0.19% | 0.00% | Sep 2026 |
| SEB Nordamerikafond Småbolag | 222K | 0.16% | -0.52% | Sep 2026 |
| HealthInvest Sustainable Healthcare E | 199K | 0.14% | +20.41% | Oct 2026 |
| TEQ- Disruptive Tech In I-III | 190K | 0.13% | +28.30% | Sep 2026 |
| Royce Small-Cap Growth Growth Svc | 178K | 0.13% | 0.00% | Sep 2026 |
| ALPS Medical Breakthroughs ETF | 170K | 0.12% | 0.00% | Oct 2026 |
| Premier Miton Diversified GrB Inc | 149K | 0.11% | -3.86% | Sep 2026 |
| Goldman Sachs Small Cap Growth P | 148K | 0.10% | 0.00% | Sep 2026 |
| T. Rowe Price Small-Mid Cap ETF | 136K | 0.10% | -1.05% | Oct 2026 |
| Vanguard Explorer Inv | 114K | 0.08% | 0.00% | Sep 2026 |
Top institutions holding CMPS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Deep Track Capital, LP | 12.2M | 8.58% | 0.00% | Jun 2026 |
| RTW INVESTMENTS, LLC | 10.7M | 7.55% | +0.65% | Jun 2026 |
| TANG CAPITAL MANAGEMENT LLC | 5.00M | 3.53% | +24.93% | Jun 2026 |
| Two Sigma Investments LLC | 4.47M | 3.15% | +73.04% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 4.33M | 3.05% | +7.19% | Jun 2026 |
| ARK Investment Management LLC | 3.45M | 2.44% | +4.57% | Jun 2026 |
| Point72 Asset Management, L.P. | 2.62M | 1.85% | 0.00% | Jun 2026 |
| Logos Global Management LP | 2.25M | 1.59% | 0.00% | Jun 2026 |
| Eagle Health Investments LP | 2.06M | 1.45% | 0.00% | Jun 2026 |
| Bank of America Corp | 2.02M | 1.43% | +6,145.66% | Jun 2026 |
| Dafna Capital Management LLC | 2.01M | 1.42% | -16.82% | Jun 2026 |
| NEXTBio Capital Management LP | 1.78M | 1.25% | -12.15% | Jun 2026 |
| Kalehua Capital Management LLC | 1.64M | 1.16% | 0.00% | Jun 2026 |
| UBS Group AG | 1.48M | 1.05% | -20.09% | Jun 2026 |
| Aisling Capital Management LP | 1.43M | 1.01% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 1.43M | 1.01% | +65.47% | Jun 2026 |
| Candriam Luxembourg S.C.A. | 1.27M | 0.90% | 0.00% | Jun 2026 |
| Woodline Partners LP | 1.09M | 0.77% | +519.02% | Jun 2026 |
| Citadel Advisors Llc | 1.00M | 0.71% | +272.88% | Jun 2026 |
| Jefferies Financial Group Inc | 994K | 0.70% | -32.23% | Jun 2026 |
Compass Pathways Plc company profile
- Company name
- Compass Pathways Plc
- Ticker
- CMPS.US
- Exchange
- USA Stocks
- Listed since
- Sep 18, 2020
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 156
- Fiscal year end
- December
- Address
- 33 Broadwick Street, London, United Kingdom, W1F 0DQ
- Phone
- 44 716 6766461
- Website
- compasspathways.com
About Compass Pathways Plc
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
Compass Pathways Plc management
10- Mr. Kabir Kumar Nath M.A., M.B.A.CEO & Executive Director · born 1964
- Ms. Teri Loxam M.B.A.Chief Financial Officer · born 1973
- Dr. Guy GoodwinChief Medical Officer · born 1948
- Mr. Stephen D. SchultzSenior Vice President of Investor Relations
- Ms. Kelley BoucherChief People Officer
- Mr. Lars Christian WildeSenior Advisor · born 1986
- Dr. Susan C. Stansfield Ph.D.Advisor
- Dr. Michael Gold M.D., M.Sc.Chief Research & Development Officer · born 1961
- Ms. Lori Englebert M.B.A.Chief Commercial Officer · born 1978
- Dr. Steve Levine M.D.Chief Patient Officer